Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
199 hedge funds and large institutions have $4.04B invested in Spark Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 42 increasing their positions, 51 reducing their positions, and 42 closing their positions.
633% more funds holding in top 10
Funds holding in top 10: 3 → 22 (+19)
163% more capital invested
Capital invested by funds: $1.54B → $4.04B (+$2.5B)
100% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 42
55% more call options, than puts
Call options by funds: $87.4M | Put options by funds: $56.3M
27% more funds holding
Funds holding: 157 → 199 (+42)
18% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$67.3M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$66M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$60.3M |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$58M |
| 5 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$50.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$271M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$186M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$145M |
| 4 |
JP Morgan Chase
New York
|
-$107M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$94M |
ONCE Hedge Fund Activity: Q1 2019 in Review
199 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q1 2019, worth a combined $4.04B — up 163% from $1.54B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new ONCE positions and 42 closed out — a net gain of 42 holders — while 42 added to existing stakes and 51 trimmed.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $67.3M. The largest seller was Fidelity Investments, cutting an estimated $271M.
- 199 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q1 2019, up from 157 in Q4 2018.
- Funds reported $4.04B of Spark Therapeutics, Inc. Common Stock stock for Q1 2019, up 163% quarter-over-quarter.
- 84 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q1 2019 and 42 closed out, a net change of +42 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q1 2019 was Magnetar Financial, an estimated $67.3M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q1 2019 was Fidelity Investments, an estimated $271M sold.
Based on aggregated 13F filings for Q1 2019.